Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Massachusetts Medicaid Adds Prior Authorization For Elidel, Protopic

This article was originally published in The Pink Sheet Daily

Executive Summary

State’s decision to require prior authorization for Novartis’ Elidel and Astellas’ Protopic comes several months after FDA requested that labeling for the topical eczema agents include a “black box” warning for potential cancer risk. MassHealth removes prior authorization requirement for Berlex’ estrogen patch Menostar.

You may also be interested in...



Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk

Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.

"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says

Although noting that data suggesting a cancer risk from the topical eczema treatments is not definitive, the panel concludes that a black box warning is the best approach to discourage off-label use. A medication guide should also be mandated, the committee says.

Berlex To Launch Menostar As Lowest Dose Estrogen Patch Approved For Osteoporosis Prevention

Low estrogen dose reduces need for concomitant progestin therapy in women who have a uterus. Berlex will study longer-term use following June 8 FDA approval.

Topics

UsernamePublicRestriction

Register

PS062666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel